Regulus (RGLS) has issued an update.
Regulus Therapeutics Inc.’s stockholders made several key decisions at the Annual Meeting on May 16, 2024, including the election of ten directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year. They also approved executive compensation and decided to hold annual advisory votes on the matter. Furthermore, an amendment to the 2019 Equity Incentive Plan was passed, increasing the authorized shares for issuance and adjusting the share reserve calculation. These decisions chart a clear course for the company’s governance and incentive structures in the coming year.
For a thorough assessment of RGLS stock, go to TipRanks’ Stock Analysis page.
